Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: The Korean atherosclerosis study (KAS) A 42-month prospective study

被引:76
作者
Lim, Soo [1 ]
Koo, Bo Kyeong [1 ]
Cho, Sun Wook [1 ]
Kihara, Shinji [2 ]
Funahashi, Tohru [2 ]
Cho, Young Min [1 ]
Kim, Seong Yeon [1 ]
Lee, Hong Kyu [1 ]
Shimomura, Iichiro [2 ]
Park, Kyong Soo [1 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea
[2] Osaka Univ, Grad Sch Med, Dept Metab Med, Suita, Osaka 565, Japan
关键词
adiponectin; resistin; cardiovascular disease; type; 2; diabetes; South Korea;
D O I
10.1016/j.atherosclerosis.2006.11.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adiponectin and resistin are proteins that affect insulin resistance and atherosclerosis significantly. We investigated adiponectin and resistin concentrations as predictors of cardiovascular events in Korean patients with type 2 diabetes. The study in 2001 comprised 343 unrelated patients with type 2 diabetes (65 +/- 9.2 years old). They were followed up for 42 months. The baseline duration of diabetes, smoking status and history of cardiovascular diseases (CVD) were recorded. BMI, blood pressures, HbA1c, lipid profiles, ECG, creatinine and urine microalbumin were measured. Adiponectin and resistin were measured using enzyme-linked immunosorbent assays. The primary endpoint was defined as one of cardiovascular death, myocardial infarct, CABG, stroke, unstable angina or overt nephropathy. Thirty-eight patients (11. 1 %) experienced primary endpoint during the follow-up. After adjustment for age, sex, BMI, blood pressure and lipid status, participants in the lowest quartile of adiponectin levels compared with the highest had significantly increased risk of primary endpoint (relative risk = 3.03; 95% CI 1.09-8.41; p = 0.034). In contrast, resistin level had no influence on the risk of primary endpoint. A low level of adiponectin, not resistin, was a significant risk factor for the development of cardiovascular events in these Korean patients with type 2 diabetes. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:398 / 404
页数:7
相关论文
共 42 条
[1]   Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity [J].
Arita, Y ;
Kihara, S ;
Ouchi, N ;
Takahashi, M ;
Maeda, K ;
Miyagawa, J ;
Hotta, K ;
Shimomura, I ;
Nakamura, T ;
Miyaoka, K ;
Kuriyama, H ;
Nishida, M ;
Yamashita, S ;
Okubo, K ;
Matsubara, K ;
Muraguchi, M ;
Ohmoto, Y ;
Funahashi, T ;
Matsuzawa, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (01) :79-83
[2]   Regulation of fasted blood glucose by resistin [J].
Banerjee, RR ;
Rangwala, SM ;
Shapiro, JS ;
Rich, AS ;
Rhoades, B ;
Qi, Y ;
Wang, J ;
Rajala, MW ;
Pocai, A ;
Scherer, PE ;
Steppan, CM ;
Ahima, RS ;
Obici, S ;
Rossetti, L ;
Lazar, MA .
SCIENCE, 2004, 303 (5661) :1195-1198
[3]   Cross-sectional associations of resistin, coronary heart disease, and insulin resistance [J].
Burnett, MS ;
Devaney, JM ;
Adenika, RJ ;
Lindsay, R ;
Howard, BV .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (01) :64-68
[4]   Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways [J].
Calabro, P ;
Samudio, I ;
Willerson, JT ;
Yeh, ETH .
CIRCULATION, 2004, 110 (21) :3335-3340
[5]   Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population - The Funagata study [J].
Daimon, M ;
Oizumi, T ;
Saitoh, T ;
Kameda, W ;
Hirata, A ;
Yamaguchi, H ;
Ohnuma, H ;
Igarashi, M ;
Tominaga, M ;
Kato, T .
DIABETES CARE, 2003, 26 (07) :2015-2020
[6]  
de Courten BV, 2004, DIABETES, V53, P1279, DOI 10.2337/diabetes.53.5.1279
[7]   Serum resistin (FIZZ3) protein is increased in obese humans [J].
Degawa-Yamauchi, M ;
Bovenkerk, JE ;
Juliar, BE ;
Watson, W ;
Kerr, K ;
Jones, R ;
Zhu, QH ;
Considine, RV .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11) :5452-5455
[8]   Adiponectin and the development of type 2 diabetes - The atherosclerosis risk in communities study [J].
Duncan, BB ;
Schmidt, MI ;
Pankow, JS ;
Bang, HJ ;
Couper, D ;
Ballantyne, CM ;
Hoogeveen, RC ;
Heiss, G .
DIABETES, 2004, 53 (09) :2473-2478
[9]   Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls [J].
Fehmann, HC ;
Heyn, J .
HORMONE AND METABOLIC RESEARCH, 2002, 34 (11-12) :671-673
[10]   Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients [J].
Hotta, K ;
Funahashi, T ;
Arita, Y ;
Takahashi, M ;
Matsuda, M ;
Okamoto, Y ;
Iwahashi, H ;
Kuriyama, H ;
Ouchi, N ;
Maeda, K ;
Nishida, M ;
Kihara, S ;
Sakai, N ;
Nakajima, T ;
Hasegawa, K ;
Muraguchi, M ;
Ohmoto, Y ;
Nakamura, T ;
Yamashita, S ;
Hanafusa, T ;
Matsuzawa, Y .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (06) :1595-1599